We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Destiny Pharma Plc | LSE:DEST | London | Ordinary Share | GB00BDHSP575 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.75 | -22.09% | 16.75 | 16.50 | 17.00 | 18.50 | 13.50 | 18.50 | 7,613,936 | 14:19:17 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -6.5M | -0.0683 | -2.45 | 15.96M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 05/7/2022 17:47 | Like the sound of these upfront payments that could be coming our way, then royalties. | barony | |
| 05/7/2022 15:24 | Destiny Pharma announces new XF-73 research programme: | sev22 | |
| 05/7/2022 08:26 | Destiny Pharma starts research into preventive drug for cancer treatment side effect: | sev22 | |
| 05/7/2022 08:01 | New XF-73 research program announced - to prevent oral mucositis (OM) in cancer and immunosuppressed patients. Equity Development's valuation remains 288p/share, as you can read in new research note here: | edmonda | |
| 29/5/2022 10:19 | DESTINY PHARMA PLC - Annual General Meeting - 27th May 2022. | sev22 | |
| 26/5/2022 21:51 | With the new appointments I see A Nasdaq listing on the horizon. ? | supracat | |
| 12/5/2022 17:21 | Neil Clark & Dr Bill Love of Destiny Pharma: World leading scientists to present landmark data on it's clinical asset NTCD-M3. | sev22 | |
| 10/5/2022 13:41 | This moves fast on small sells and buys !! | s34icknote | |
| 09/5/2022 12:48 | The share price here is ridiculously undervalued. £31m for 2x Phase 3 ready assets with excellent data behind them! And they raised £6.5m cash less than 2 months ago so have zero need for funding! | sicilian_kan | |
| 03/5/2022 09:19 | https://twitter.com/ | sev22 | |
| 03/5/2022 07:50 | https://www.proactiv | sev22 | |
| 03/5/2022 07:43 | Great appointment today. Our new CMO's role was: "Senior Vice President Development and deputy CMO at Grünenthal Group where he was a key member of the Global R&D Leadership and the Global Commercial Leadership Teams. Yuri has been responsible for advancing the Grünenthal Group R&D pipeline, including two phase 3 assets, two phase 2 assets and several early and pre-clinical assets. Yuri has also been a key member and driver in several in-licensing and out-licensing activities and in the completion of the acquisition of Mestex AG." Note that the Grünenthal Group had revenues of €1.4bn in 2019. Now why would someone like that come to little old Destiny Pharma (market cap just £34m)... | sicilian_kan | |
| 13/4/2022 18:31 | DESTINY PHARMA PLC - Audited results for the year ended 31 December 2021 (12th April 2022). | sev22 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
